Supernus Pharmaceuticals, Inc.
SUPN
$50.29
$0.380.76%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 10.13% | 16.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.13% | 16.11% | |||
| Cost of Revenue | -214.63% | 187.22% | |||
| Gross Profit | 85.69% | -3.27% | |||
| SG&A Expenses | 77.85% | 17.37% | |||
| Depreciation & Amortization | 0.83% | 16.84% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 48.52% | 19.00% | |||
| Operating Income | -821.56% | -23.93% | |||
| Income Before Tax | 96.70% | -447.68% | |||
| Income Tax Expenses | 117.07% | -120.19% | |||
| Earnings from Continuing Operations | 90.90% | -300.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 90.90% | -300.53% | |||
| EBIT | -821.56% | -23.93% | |||
| EBITDA | -208.58% | 2.41% | |||
| EPS Basic | 91.03% | -298.66% | |||
| Normalized Basic EPS | -638.47% | -32.04% | |||
| EPS Diluted | 90.96% | -300.00% | |||
| Normalized Diluted EPS | -638.47% | -31.29% | |||
| Average Basic Shares Outstanding | 1.40% | 0.94% | |||
| Average Diluted Shares Outstanding | 1.40% | -0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||